<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Par Pharmaceutical Companies Inc</title>
	<atom:link href="http://www.stockbloghub.com/tag/par-pharmaceutical-companies-inc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Thu, 24 May 2012 23:16:35 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(MYL) Mylan Settles with Roche for Xeloda</title>
		<link>http://www.stockbloghub.com/2011/09/23/myl-mylan-settles-with-roche-for-xeloda/83911</link>
		<comments>http://www.stockbloghub.com/2011/09/23/myl-mylan-settles-with-roche-for-xeloda/83911#comments</comments>
		<pubDate>Fri, 23 Sep 2011 19:05:09 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83911</guid>
		<description><![CDATA[Mylan Inc. (MYL) recently announced that it has entered into a settlement and license agreement with Roche (RHHBY) bringing an end to its ongoing litigation with the latter relating to Roche’s cancer drug Xeloda. Mylan was looking to launch a generic version of the drug which is used for the treatment of metastatic breast and colorectal cancers. Xeloda generated revenue of $570 million in the trailing twelve months ending June 30, 2011, according to IMS Health. The details of the agreement have been kept confidential. The agreement will be applicable once it is reviewed by the US Department of Justice and the Federal Trade Commission. Mylan also recently announced that its Indian subsidiary, Matrix, has received tentative approval from the US Food and Drug Administration (FDA) to market a novel ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/23/myl-mylan-settles-with-roche-for-xeloda/83911/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan Analyst Reaffirms Shares at Neutral</title>
		<link>http://www.stockbloghub.com/2011/08/25/myl-mylan-analyst-reaffirms-shares-at-neutral/81823</link>
		<comments>http://www.stockbloghub.com/2011/08/25/myl-mylan-analyst-reaffirms-shares-at-neutral/81823#comments</comments>
		<pubDate>Thu, 25 Aug 2011 16:48:21 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=81823</guid>
		<description><![CDATA[We have maintained our Neutral recommendation on Mylan Inc. (MYL) with a target price of $19.00 following an appraisal of second quarter 2011 financial results. Mylan’s second quarter 2011 earnings (excluding special items) of 52 cents per share were above the Zacks Consensus Estimate of 45 cents and also beat the year-ago earnings 37 cents. Earnings growth was driven by an increase in generics revenue and improved gross margins. Mylan reports revenues from two segments: Generics and Specialty. Generic revenues grew 17% to $1.44 billion in the second quarter of 2011 as a decline in the Europe, Middle East &#38; Africa (EMEA) market was offset by growth in other markets like Asia-Pacific and North America. Mylan is one of the leading players in the generics market. A large number of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/25/myl-mylan-analyst-reaffirms-shares-at-neutral/81823/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan and Endo Pharmaceuticals in Legal Tussle</title>
		<link>http://www.stockbloghub.com/2011/08/18/myl-mylan-and-endo-pharmaceuticals-in-legal-tussle/81630</link>
		<comments>http://www.stockbloghub.com/2011/08/18/myl-mylan-and-endo-pharmaceuticals-in-legal-tussle/81630#comments</comments>
		<pubDate>Thu, 18 Aug 2011 22:40:07 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Endo Pharmaceuticals Holdings Inc]]></category>
		<category><![CDATA[ENDP]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=81630</guid>
		<description><![CDATA[Mylan Inc. (MYL) recently announced that Endo Pharmaceuticals (ENDP) filed a patent infringement lawsuit in connection with an abbreviated new drug application (ANDA) filed by Mylan with the US Food and Drug Administration (FDA) for the generic version of Endo’s acute migraine drug Frova. Mylan believes it is the first company to file an ANDA for generic Frova and is expecting to be granted 180 days of marketing exclusivity once approved. Frova generated revenues of approximately $68.2 million in the trailing twelve months ending on June 30, 2011. This month, Mylan launched the generic version of Uroxatral tablets. Some important products launched by Mylan in the recent past include generic versions of AstraZeneca&#8216;s (AZN) Entocort, Novartis&#8216; (NVS) Femara and Cephalon&#8216;s (CEPH) Amrix. Mylan has a robust generic pipeline. As of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/18/myl-mylan-and-endo-pharmaceuticals-in-legal-tussle/81630/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan Beats Second Quarter Earnings on All Fronts</title>
		<link>http://www.stockbloghub.com/2011/07/27/myl-mylan-beats-second-quarter-earnings-on-all-fronts/80033</link>
		<comments>http://www.stockbloghub.com/2011/07/27/myl-mylan-beats-second-quarter-earnings-on-all-fronts/80033#comments</comments>
		<pubDate>Thu, 28 Jul 2011 04:22:53 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Advanced Photonix Inc.]]></category>
		<category><![CDATA[API]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80033</guid>
		<description><![CDATA[Mylan Inc.’s (MYL) second quarter 2011 earnings (excluding special items) of 52 cents per share were above the Zacks Consensus Estimate of 45 cents as well as the year-ago earnings of 37 cents per share. Earnings growth was driven by increase in generics revenue and improved gross margins. Quarter in Details Total revenues at Mylan climbed 15% over the prior year to $1.57 billion driven by increased sales of generic drugs and the positive impact of foreign exchange (Fx). Revenues were also ahead of the Zacks Consensus Estimate of $1.50 billion. Total revenues comprise both net revenues and other revenues from third parties. Mylan reports revenues through two segments: Generics and Specialty. Generic third party net sales, derived from sales in North America, Europe, Middle East &#38; Africa (EMEA), and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/27/myl-mylan-beats-second-quarter-earnings-on-all-fronts/80033/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan Gets HIV Rights from Gilead</title>
		<link>http://www.stockbloghub.com/2011/07/14/myl-mylan-gets-hiv-rights-from-gilead/79031</link>
		<comments>http://www.stockbloghub.com/2011/07/14/myl-mylan-gets-hiv-rights-from-gilead/79031#comments</comments>
		<pubDate>Thu, 14 Jul 2011 16:42:01 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=79031</guid>
		<description><![CDATA[Mylan, Inc. (MYL) recently announced that its Indian subsidiary Matrix Laboratories has been granted future rights to produce and sell generic versions of three investigational HIV therapies of Gilead Sciences, Inc. (GILD), if and when approved. The agreement aims to expand access to HIV therapies in developing nations. The therapies include elvitegravir, an integrase inhibitor; cobicistat, an antiretroviral (ARV) boosting agent; and the &#8220;Quad,&#8221; a once-daily combination pill of elvitegravir, cobicistat and Gilead’s another HIV combination medicine Truvada (Emtriva+Viread). The rights are an extension of the non-exclusive license granted to Matrix to produce and sell active pharmaceutical ingredients and finished products, including generic versions of Viread and Truvada in 95 developing countries including India. The license has now been expanded to include 16 additional countries, the three investigational medicines and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/14/myl-mylan-gets-hiv-rights-from-gilead/79031/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PRX) Par Pharmaceutical Restructures Branded Business</title>
		<link>http://www.stockbloghub.com/2011/07/05/prx-par-pharmaceutical-restructures-branded-business/78319</link>
		<comments>http://www.stockbloghub.com/2011/07/05/prx-par-pharmaceutical-restructures-branded-business/78319#comments</comments>
		<pubDate>Tue, 05 Jul 2011 14:22:57 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78319</guid>
		<description><![CDATA[Par Pharmaceutical Companies, Inc. (PRX) is in for a strategic assessment as it announced restructuring plans for its branded drugs segment, Strativa Pharmaceuticals. The company will reduce its workforce by about 100 people as a result of the restructuring, which is expected to drive the Strativa business to profitability. The workforce reduction will help Par Pharma focus on its products, Megace ES and Nascobal. Consequently, in the second quarter of 2011, Par Pharma will incur one-time non-cash charges along with severance costs. The restructuring initiative is expected to generate operating expense savings of $8-$12 million for the rest of 2011. The company believes this initiative will boost Strativa to profitability in the near term. We expect the restructuring program to benefit the company, which witnessed a 20.9% drop in revenues ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/05/prx-par-pharmaceutical-restructures-branded-business/78319/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Trial Date for Teva Pharmaceuticals / Mylan Dispute</title>
		<link>http://www.stockbloghub.com/2011/06/22/myl-trial-date-for-teva-pharmaceuticals-mylan-dispute/77026</link>
		<comments>http://www.stockbloghub.com/2011/06/22/myl-trial-date-for-teva-pharmaceuticals-mylan-dispute/77026#comments</comments>
		<pubDate>Wed, 22 Jun 2011 14:58:23 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Canadian Pacific Railway Limited]]></category>
		<category><![CDATA[CP]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77026</guid>
		<description><![CDATA[Mylan Inc. (MYL) received some good news recently when a US District court denied Teva Pharmaceuticals Industries’ (TEVA) motion for a summary judgment, finding no inequitable conduct in the Copaxone infringement lawsuit. The court has ordered that the trial for inequitable conduct defense will commence on July 11, 2011. The remaining issues will be tried from September 7, 2011. Teva is challenging Mylan’s application for making a generic version of Teva&#8217;s Copaxone, a top selling drug for the treatment of multiple sclerosis. Copaxone loses patent protection in 2014. In December 2010 Teva filed a Citizen Petition (CP) with the FDA asking the agency to refuse approval to generic versions of Copaxone. The company said that any generic version of Copaxone should be subject to pre-clinical studies as well as full-scale ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/22/myl-trial-date-for-teva-pharmaceuticals-mylan-dispute/77026/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan Launches New Generic Pharmaceuticals</title>
		<link>http://www.stockbloghub.com/2011/05/27/myl-mylan-launches-new-generic-pharmaceuticals/75053</link>
		<comments>http://www.stockbloghub.com/2011/05/27/myl-mylan-launches-new-generic-pharmaceuticals/75053#comments</comments>
		<pubDate>Fri, 27 May 2011 13:40:29 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ISTA]]></category>
		<category><![CDATA[ISTA Pharmaceuticals Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=75053</guid>
		<description><![CDATA[Mylan Inc.’s (MYL) generic portfolio continued to be boosted with the launch of the generic version of Xanodyne Pharmaceutical’s pain reliever Roxicodone. The generic has been launched under a development and supply agreement with Coastal Pharmaceuticals. The product recorded sales of $325 million in US for the twelve months endied March 31, 2011 according to data released by IMS Health. We note that the launch of the generic version of the pain reliever is the latest in the series of generic launches at Mylan. A couple of days ago the company, which is one of the largest generic and specialty pharmaceutical companies across the globe, launched its generic version of Abbott Laboratories’ (ABT) Depakote Sprinkle Capsules for treating seizures. The product recorded sales of $89 million in US for the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/27/myl-mylan-launches-new-generic-pharmaceuticals/75053/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan Launches Generic Drugs</title>
		<link>http://www.stockbloghub.com/2011/05/21/myl-mylan-launches-generic-drugs/74321</link>
		<comments>http://www.stockbloghub.com/2011/05/21/myl-mylan-launches-generic-drugs/74321#comments</comments>
		<pubDate>Sat, 21 May 2011 13:54:36 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[ISTA]]></category>
		<category><![CDATA[ISTA Pharmaceuticals Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=74321</guid>
		<description><![CDATA[MylanInc. (MYL) recently launched its generic version of Ista Pharmaceuticals Inc’s (ISTA) Xibrom ophthalmic solution, used for the treatment of inflammation in patients who have undergone a cataract extraction operation. The generic has been launched under a development and supply agreement with Coastal Pharmaceuticals. The branded product recorded sales of $116 million in US for the twelve months ending on March 31, 2011. Mylan also recently announced launches of generic versions of Cephalon’s (CEPH) Amrix which is a muscle relaxant and Johnson &#38; Johnson’s (JNJ) Risperdal which is used for the treatment of schizophrenia. As of May 16, 2011, the company had 169 abbreviated new drug applications (ANDAs) pending US Food and Drug Administration (FDA) approval targeting $100.7 billion in branded sales. Mylan believes that about 45 of the pending ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/21/myl-mylan-launches-generic-drugs/74321/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan Meets Analyst Estimates &#8211; Sales Upbeat</title>
		<link>http://www.stockbloghub.com/2011/05/03/myl-mylan-meets-analyst-estimates-sales-upbeat/73045</link>
		<comments>http://www.stockbloghub.com/2011/05/03/myl-mylan-meets-analyst-estimates-sales-upbeat/73045#comments</comments>
		<pubDate>Tue, 03 May 2011 18:03:17 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Advanced Photonix Inc.]]></category>
		<category><![CDATA[API]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73045</guid>
		<description><![CDATA[Mylan Inc.’s (MYL) first quarter 2011 earnings (excluding special items) of 44 cents per share were in line with the Zacks Consensus Estimate. A higher quarterly tax rate, increased share count and pricing pressure in Europe offset the increase in generics revenue in North America to deliver in line earnings growth. Earnings were nevertheless 22% above year-ago earnings of 36 cents per share. Quarter in Details Total revenues at Mylan climbed 12.1% over the prior year to $1.45 billion driven by increased sales of generic drugs. Revenue was also barely above the Zacks Consensus Estimate of $1.44 billion. Total revenues comprises both net revenues and other revenues from third parties. Mylan reports revenues from two segments: Generics and Specialty. Generic third party net sales, derived from sales in North America, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/03/myl-mylan-meets-analyst-estimates-sales-upbeat/73045/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan Analyst Maintains Neutral Rating on Shares</title>
		<link>http://www.stockbloghub.com/2011/03/20/myl-mylan-analyst-maintains-neutral-rating-on-shares/69247</link>
		<comments>http://www.stockbloghub.com/2011/03/20/myl-mylan-analyst-maintains-neutral-rating-on-shares/69247#comments</comments>
		<pubDate>Mon, 21 Mar 2011 03:26:17 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=69247</guid>
		<description><![CDATA[We have maintained our Neutral recommendation on Mylan Inc. (MYL) with a target price of $23.00 after appraising fourth quarter and fiscal year 2010 financial results. Mylan’s fourth quarter 2010 earnings (excluding special items) of 45 cents per share were at par with the Zacks Consensus Estimate. Higher operating expenses offset the increase in revenue to deliver in line earnings growth. Earnings were however well above the year-ago figure of 33 cents per share. Revenues climbed 6% to $1.43 billion but fell short of the Zacks Consensus Estimate of $1.46 billion. Mylan reports revenues from two segments: Generics and Specialty. Generic revenues grew 5.5% to $1.35 billion in the final quarter of 2010 as a decline in the Europe, Middle East &#38; Africa (EMEA) market was offset by growth in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/03/20/myl-mylan-analyst-maintains-neutral-rating-on-shares/69247/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(WPI) Watson Pharmaceuticals Analyst Maintains Neutral Rating on Shares</title>
		<link>http://www.stockbloghub.com/2011/03/17/wpi-watson-pharmaceuticals-analyst-maintains-neutral-rating-on-shares/68917</link>
		<comments>http://www.stockbloghub.com/2011/03/17/wpi-watson-pharmaceuticals-analyst-maintains-neutral-rating-on-shares/68917#comments</comments>
		<pubDate>Thu, 17 Mar 2011 17:02:54 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health Inc.]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[RDY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Warner Chilcott Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WCRX]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=68917</guid>
		<description><![CDATA[We recently reaffirmed our Neutral stance on Watson Pharmaceuticals Inc. (WPI) following the release of fourth quarter and fiscal year 2010 financial results. Quarterly earnings of 93 cents per share were in line with the Zacks Consensus Estimate and 8 cents above the year-ago earnings. Revenues increased 21.2% to $952.7 million, mainly due to the strong performance of the generics business. Fourth quarter revenues surpassed the Zacks Consensus Estimate of $921 million. For full year 2010, Watson Pharma earned $3.42 per share (up 12.5%) on revenues of $3.6 billion (up 28%). The Zacks Consensus Estimate for 2010 was $3.42 per share on revenues of $3.5 billion. We believe that the company’s cost saving initiative and new product launches, both branded and generic, will help drive growth. We have raised our ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/03/17/wpi-watson-pharmaceuticals-analyst-maintains-neutral-rating-on-shares/68917/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SNTS) Santarus Earnings Hit by Zegerid Conversion to Generic</title>
		<link>http://www.stockbloghub.com/2010/11/17/snts-santarus-earnings-hit-by-zegerid-conversion-to-generic/59584</link>
		<comments>http://www.stockbloghub.com/2010/11/17/snts-santarus-earnings-hit-by-zegerid-conversion-to-generic/59584#comments</comments>
		<pubDate>Thu, 18 Nov 2010 05:06:22 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[DEPO]]></category>
		<category><![CDATA[DepoMed Inc]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[Santarus Inc]]></category>
		<category><![CDATA[SNTS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=59584</guid>
		<description><![CDATA[Santarus Inc. (SNTS) reported a loss of 32 cents per share in the third quarter, wider than the Zacks Consensus Estimate of a loss of 21 cents and the year-ago earnings of 9 cents. Results were affected by lower revenues following the genericization of Zegerid. Total revenues, consisting of net product sales, promotion revenues and license and royalty revenues, came in at $18.1 million, down 54.2% from the year-ago period and $3.9 million below the Zacks Consensus Estimate. Quarter in Details Product-related revenues, which consist of net product sales and promotion revenues, plunged 53.5% to $17.8 million during the reported quarter. Zegerid net product sales Incorporatedluding sales of the authorized generic version, were $11 million, down 65%. Following the launch of generic versions of Zegerid by Par Pharmaceuticals (PRX) in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/17/snts-santarus-earnings-hit-by-zegerid-conversion-to-generic/59584/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SNTS) Santarus Earnings Beat Expectations on Higher Revenues</title>
		<link>http://www.stockbloghub.com/2010/08/06/snts-santarus-earnings-beat-expectations-on-higher-revenues/46664</link>
		<comments>http://www.stockbloghub.com/2010/08/06/snts-santarus-earnings-beat-expectations-on-higher-revenues/46664#comments</comments>
		<pubDate>Fri, 06 Aug 2010 17:07:59 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[DEPO]]></category>
		<category><![CDATA[DepoMed Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[Santarus Inc]]></category>
		<category><![CDATA[SNTS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=46664</guid>
		<description><![CDATA[Santarus Inc. (SNTS) reported second-quarter earnings of 10 cents per share, well above the Zacks Consensus Estimate of 4 cents and the year-ago earnings of 2 cents. Total revenues, consisting of net product sales, promotion revenues and license and royalty revenues came in at $41.7 million, up 16.5% from the year-ago period and $4.7 million above the Zacks Consensus Estimate. Quarter in Details Product-related revenues, which consist of net product sales and promotion revenues Incorporatedreased 22% to $41 million during the reported quarter. Zegerid net product sales were $32.9 million, up 17.5%. Following the launch of generic versions of Zegerid by Par Pharmaceuticals (PRX) in late June, Santarus has stopped promoting Zegerid and has also launched an authorized generic version of Zegerid with Prasco. Meanwhile, Santarus will continue receiving royalty ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/06/snts-santarus-earnings-beat-expectations-on-higher-revenues/46664/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SNTS) Santarus&#8217; Quarterly Earnings Report Strongly Beats Expectations</title>
		<link>http://www.stockbloghub.com/2010/05/13/snts-santarus-quarterly-earnings-report-strongly-beats-expectations/37117</link>
		<comments>http://www.stockbloghub.com/2010/05/13/snts-santarus-quarterly-earnings-report-strongly-beats-expectations/37117#comments</comments>
		<pubDate>Thu, 13 May 2010 20:56:58 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[DEPO]]></category>
		<category><![CDATA[DepoMed Inc]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[Santarus Inc]]></category>
		<category><![CDATA[SNTS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=37117</guid>
		<description><![CDATA[Santarus, Inc. (SNTS) reported first-quarter earnings of 5 cents per share, well above the Zacks Consensus Estimate of a loss of one cent and the year-ago earnings of 2 cents. Total revenues, consisting of net product sales, promotion revenues and license and royalty revenues came in at $39.7 million, up 14% from the year-ago period. Product-related revenues, which consist of net product sales and promotion revenues Incorporatedreased 18% to $37.8 million during the reported quarter. Zegerid net product sales were $29 million, up 5%. However, total prescriptions declined 19% in the reported quarter following Santarus’ decision to exit from non-performing government and managed care contracts. We believe that Zegerid prescriptions will remain slightly down to flat in the first half of 2010. Zegerid over-the-counter (OTC) was launched recently by Merck (MRK). ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/13/snts-santarus-quarterly-earnings-report-strongly-beats-expectations/37117/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SNTS) Santarus Suffers Negative Patent Infringement Court Ruling</title>
		<link>http://www.stockbloghub.com/2010/04/15/snts-santarus-suffers-negative-patent-infringement-court-ruling/34023</link>
		<comments>http://www.stockbloghub.com/2010/04/15/snts-santarus-suffers-negative-patent-infringement-court-ruling/34023#comments</comments>
		<pubDate>Thu, 15 Apr 2010 23:18:50 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[DEPO]]></category>
		<category><![CDATA[DepoMed Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[Santarus Inc]]></category>
		<category><![CDATA[SNTS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=34023</guid>
		<description><![CDATA[Santarus, Inc. (SNTS) suffered a major setback recently when a US District Court ruled against the company in a patent infringement case. The U.S. District Court for the District of Delaware ruled that five patents covering the company’s flagship product, Zegerid, are invalid. Santarus had initiated the patent infringement case against generic player Par Pharmaceutical, Inc. (PRX). Par is seeking to launch its versions of Zegerid capsules and powder for oral suspension. This ruling is a huge blow for Santarus, which was looking to protect Zegerid from generic competition. The company is entirely dependent on Zegerid for growth and the entry of generic versions of the product will be devastating for the company. Zegerid accounted for 69% of total revenues in 2009. Although Santarus has been exploring other avenues to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/15/snts-santarus-suffers-negative-patent-infringement-court-ruling/34023/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PRX) Par Pharmaceutical Companies &#8211; Earnings Surprised in the Fourth Quarter by 14%</title>
		<link>http://www.stockbloghub.com/2010/04/09/prx-par-pharmaceutical-companies-earnings-surprised-in-the-fourth-quarter-by-14/33279</link>
		<comments>http://www.stockbloghub.com/2010/04/09/prx-par-pharmaceutical-companies-earnings-surprised-in-the-fourth-quarter-by-14/33279#comments</comments>
		<pubDate>Fri, 09 Apr 2010 21:39:05 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=33279</guid>
		<description><![CDATA[Par Pharmaceutical Companies Inc. (PRX) has surprised on the Zacks Consensus Estimate 4 quarters in a row by an average of 47%. PRX is trading with a forward P/E of only 12.6. Company Description Par Pharmaceutical manufactures generic drugs and branded pharmaceuticals for the specialty markets. The company ranks among the top ten in generic drug sales in the United States. It has two divisions, Par Pharmaceutical, its generic drug segment, and Strativa Pharmaceuticals, its proprietary products segment which launched in 2005. It currently markets and/or licenses more than 85 prescription drug products and has more than 30 products in active development. Par Surprised in the Fourth Quarter by 14% On Feb 24, Par Pharmaceutical reported fourth quarter results which beat the Zacks consensus by 8 cents. Earnings per share ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/09/prx-par-pharmaceutical-companies-earnings-surprised-in-the-fourth-quarter-by-14/33279/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SNTS) Santarus Heartburn Drug Over-The-Counter Version Launched</title>
		<link>http://www.stockbloghub.com/2010/04/06/snts-santarus-heartburn-drug-over-the-counter-version-launched/32934</link>
		<comments>http://www.stockbloghub.com/2010/04/06/snts-santarus-heartburn-drug-over-the-counter-version-launched/32934#comments</comments>
		<pubDate>Tue, 06 Apr 2010 20:38:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[Santarus Inc]]></category>
		<category><![CDATA[SNTS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=32934</guid>
		<description><![CDATA[Santarus Inc. (SNTS) recently announced the launch of the over-the-counter (OTC) version of its flagship product, Zegerid. OTC Zegerid is being promoted in North America by Merck’s (MRK) consumer health care subsidiary, Schering-Plough HealthCare Products Inc. The product gained approval from the US Food and Drug Administration (FDA) on December 1, 2009. The OTC version has been developed under Santarus’ agreement with Merck whereby Merck gained exclusive rights for the development, manufacture and sale of Zegerid OTC products in the US and Canada. The OTC version received approval from the FDA for OTC treatment of frequent heartburn. Zegerid is Santarus’ lead product. Santarus markets the Zegerid family of products, which are proprietary immediate-release formulations that combine omeprazole (Prilosec), a PPI, and one or more antacids. Zegerid is approved by the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/06/snts-santarus-heartburn-drug-over-the-counter-version-launched/32934/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SNTS) Santarus Beats Earnings Expectations on Higher Revenues</title>
		<link>http://www.stockbloghub.com/2010/03/08/snts-santarus-beats-earnings-expectations-on-higher-revenues/29946</link>
		<comments>http://www.stockbloghub.com/2010/03/08/snts-santarus-beats-earnings-expectations-on-higher-revenues/29946#comments</comments>
		<pubDate>Mon, 08 Mar 2010 15:27:38 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[DEPO]]></category>
		<category><![CDATA[DepoMed Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[Santarus Inc]]></category>
		<category><![CDATA[SNTS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=29946</guid>
		<description><![CDATA[Santarus, Inc. (SNTS) reported fourth quarter earnings of 40 cents per share, doubling the Zacks Consensus Estimate of 20 cents and far above the year-ago earnings of 7 cents. Performance was boosted by higher revenues. Total revenues, consisting of net product sales, promotion revenues and license and royalty revenues came in at $62.4 million, up 66.3% from the year-ago period. Fourth quarter revenues included a $20 million milestone payment received by the company from Merck (MRK) on the approval of the over-the-counter (OTC) version of Zegerid. Full-year earnings came in at 54 cents, well above the year-ago loss of 9 cents. Total revenues, consisting of net product sales, promotion revenues, and license and royalty revenues increased 32% to $172.5 million. The Quarter in Detail Product-related revenues, which consist of net ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/08/snts-santarus-beats-earnings-expectations-on-higher-revenues/29946/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(WPI) Watson Pharmaceuticals Sees 16 Analysts Raising Fourth Quarter Estimates</title>
		<link>http://www.stockbloghub.com/2010/01/27/wpi-watson-pharmaceuticals-sees-16-analysts-raising-fourth-quarter-estimates/26214</link>
		<comments>http://www.stockbloghub.com/2010/01/27/wpi-watson-pharmaceuticals-sees-16-analysts-raising-fourth-quarter-estimates/26214#comments</comments>
		<pubDate>Thu, 28 Jan 2010 01:24:20 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[RDY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=26214</guid>
		<description><![CDATA[Watson Pharmaceuticals, Inc. (WPI) reports fourth-quarter results on February 23, with the current Zacks Consensus Estimate at 72 cents per share. Estimates appear to be modestly up, with one of the 16 analysts covering the stock raising fourth quarter estimates in the last 30 days. In terms of earnings surprises, Watson had a modest positive surprise in the third quarter and a 7% positive surprise in the second quarter of 2009, with the four-quarter average of 8%. (This means, on average, Watson has come ahead of the Zacks Consensus by 8% over the last four quarters.) If quarterly results come in-line with expectations, fourth quarter 2009 EPS would be 35.8% above the year-ago level. However, chances are high that there could be a positive surprise of 1.4% for the upcoming ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/27/wpi-watson-pharmaceuticals-sees-16-analysts-raising-fourth-quarter-estimates/26214/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(WPI) Watson Pharmaceuticals Set to Top Expectations</title>
		<link>http://www.stockbloghub.com/2010/01/14/wpi-watson-pharmaceuticals-set-to-top-expectations/25019</link>
		<comments>http://www.stockbloghub.com/2010/01/14/wpi-watson-pharmaceuticals-set-to-top-expectations/25019#comments</comments>
		<pubDate>Thu, 14 Jan 2010 22:21:31 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[JPM]]></category>
		<category><![CDATA[JPMorgan Chase & Company]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[RDY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=25019</guid>
		<description><![CDATA[Watson Pharmaceuticals, Inc. (WPI) recently announced that it expects 2009 earnings to meet or exceed guidance provided by the company in Nov. 2009. The company had earlier guided towards earnings in the range of $2.50 &#8211; $2.58 per share. Watson also announced that it expects revenues to increase 9% year over year to $2.7 billion in 2009. The company’s shares reacted positively to the news, with the stock gaining roughly 3.5% since the announcement. The statement, which was made at the 28th Annual J.P. Morgan (JPM) Healthcare Conference, is based on a preliminary review of the company’s performance in the fourth quarter and year-ended December 31, 2009. Watson attributed the robust performance to strong contributions from its new generic and brand products, and significant growth in distribution revenues in the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/14/wpi-watson-pharmaceuticals-set-to-top-expectations/25019/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(WPI) Watson Pharmaceuticals Coverage Initiated at Neutral</title>
		<link>http://www.stockbloghub.com/2010/01/10/wpi-watson-pharmaceuticals-coverage-initiated-at-neutral/24593</link>
		<comments>http://www.stockbloghub.com/2010/01/10/wpi-watson-pharmaceuticals-coverage-initiated-at-neutral/24593#comments</comments>
		<pubDate>Sun, 10 Jan 2010 23:33:23 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[RDY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=24593</guid>
		<description><![CDATA[We recently initiated coverage on Watson Pharmaceuticals, Inc. (WPI) with a “Neutral&#8221; recommendation and a target price of $42. The company enjoys a strong position in the generics market. We believe the company’s strategy of developing generics that are difficult to formulate or manufacture will help strengthen its position in the market. Going forward Incorporatedreasing awareness about generics, initiatives taken by various government and private agencies encouraging the use of low-cost generics, an aging population and a corresponding increase in healthcare costs, as well as the large number of branded products losing patent protection over the coming years, should lead to continued expansion of the generics market. We also believe that Watson’s recent acquisition of Arrow will help the company expand its footprint in ex-U.S. territories, and will also boost ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/10/wpi-watson-pharmaceuticals-coverage-initiated-at-neutral/24593/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SNTS) Santarus Recently Downgraded to Neutral</title>
		<link>http://www.stockbloghub.com/2010/01/06/snts-santarus-recently-downgraded-to-neutral/24280</link>
		<comments>http://www.stockbloghub.com/2010/01/06/snts-santarus-recently-downgraded-to-neutral/24280#comments</comments>
		<pubDate>Wed, 06 Jan 2010 17:23:11 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[DEPO]]></category>
		<category><![CDATA[DepoMed Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[Santarus Inc]]></category>
		<category><![CDATA[SNTS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=24280</guid>
		<description><![CDATA[We recently downgraded our recommendation on specialty pharmaceutical company Santarus Inc. (SNTS) to Neutral. Santarus is focused on the acquisition, development, and commercialization of proprietary products and therapies that have the potential to treat gastrointestinal diseases and disorders Incorporatedluding gastroesophageal reflux disease (GERD). Santarus primarily focuses on the commercialization of proprietary immediate-release proton pump inhibitor (PPI) products. Flagship product, Zegerid, has captured a nice niche in the GERD market, and the company has good upside potential with the product through partnerships with GlaxoSmithKline (GSK), Norgine and Merck (MRK). The launch of the tablet and over the counter (OTC) formulations of Zegerid in 2010, as well as the launch of Zegerid around Europe by EU partner, GlaxoSmithKline, all present potential positive catalysts for Santarus. We are also excited about the recent ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/06/snts-santarus-recently-downgraded-to-neutral/24280/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PRX) Par Pharmaceutical Cos. &#8211; Revenue Doubles &#8211; Earnings Estimates Jump</title>
		<link>http://www.stockbloghub.com/2009/12/04/prx-par-pharmaceutical-cos-revenue-doubles-earnings-estimates-jump/22005</link>
		<comments>http://www.stockbloghub.com/2009/12/04/prx-par-pharmaceutical-cos-revenue-doubles-earnings-estimates-jump/22005#comments</comments>
		<pubDate>Sat, 05 Dec 2009 02:04:20 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=22005</guid>
		<description><![CDATA[Par Pharmaceutical Cos. (PRX) continues to climb as analysts raise estimates on another earnings surprise. Company Description Par Pharmaceutical makes generic drugs and other branded pharmaceuticals. Currently, the company has 4 trademarked drugs and numerous generics. Revenue Doubles The company&#8217;s third-quarter results, released Nov 6, showed revenue of $295 million, up from $149 million last year. This lead to net income of $26.3 million, exponentially higher than the $0.5 million at the same time last year. Earnings per share came in at 77 cents, compared to just 1 penny last year. Analysts were looking for just 49 cents, making this the third consecutive earnings surprise. Estimates Jump The Zacks Consensus Estimate for full-year 2009 and 2010 both jumped on the news. Current year forecasts are averaging $2.46, up from $1.88. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/04/prx-par-pharmaceutical-cos-revenue-doubles-earnings-estimates-jump/22005/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PRX) Par Pharmaceutical Companies, Inc. &#8211; Beat by 35.42% in the Second Quarter</title>
		<link>http://www.stockbloghub.com/2009/10/21/prx-par-pharmaceutical-companies-inc-beat-by-35-42-in-the-second-quarter/18350</link>
		<comments>http://www.stockbloghub.com/2009/10/21/prx-par-pharmaceutical-companies-inc-beat-by-35-42-in-the-second-quarter/18350#comments</comments>
		<pubDate>Wed, 21 Oct 2009 23:15:11 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=18350</guid>
		<description><![CDATA[Par Pharmaceutical Companies, Inc. (PRX) has surprised on the Zacks Consensus Estimate 3 out of the last 4 quarters by an average of 101.93%. With earnings estimates jumping, the company has a PEG ratio of just 0.2. Company Description Par Pharmaceutical manufactures generic drugs and branded pharmaceuticals for the specialty markets. The company ranks among the top ten in generic drug sales in the United States. The branded division, Strativa Pharmaceuticals, was launched in 2005 and has licensed 4 proprietary drugs that are in development. Third Quarter Zacks Consensus Estimate Rises As the third quarter earnings report scheduled for Nov 5 approaches, analysts are becoming more bullish on Par. In just the last week, 3 out of 8 covering analysts have raised estimates by 3 cents to 47 cents per ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/21/prx-par-pharmaceutical-companies-inc-beat-by-35-42-in-the-second-quarter/18350/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PRX) Par Pharmaceutical Companies &#8211; Beat by 35.42% in the Second Quarter</title>
		<link>http://www.stockbloghub.com/2009/10/20/prx-par-pharmaceutical-companies-beat-by-35-42-in-the-second-quarter/18169</link>
		<comments>http://www.stockbloghub.com/2009/10/20/prx-par-pharmaceutical-companies-beat-by-35-42-in-the-second-quarter/18169#comments</comments>
		<pubDate>Tue, 20 Oct 2009 20:33:58 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=18169</guid>
		<description><![CDATA[Par Pharmaceutical Companies, Inc. (PRX) has surprised on the Zacks Consensus Estimate 3 out of the last 4 quarters by an average of 101.93%. With earnings estimates jumping, the company has a PEG ratio of just 0.2. Company Description Par Pharmaceutical manufactures generic drugs and branded pharmaceuticals for the specialty markets. The company ranks among the top ten in generic drug sales in the United States. The branded division, Strativa Pharmaceuticals, was launched in 2005 and has licensed 4 proprietary drugs that are in development. Third Quarter Zacks Consensus Estimate Rises As the third quarter earnings report scheduled for Nov 5 approaches, analysts are becoming more bullish on Par. In just the last week, 3 out of 8 covering analysts have raised estimates by 3 cents to 47 cents per ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/20/prx-par-pharmaceutical-companies-beat-by-35-42-in-the-second-quarter/18169/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PRX) Top Performer for Thurs: Par Pharmaceutical Companies</title>
		<link>http://www.stockbloghub.com/2009/10/15/prx-top-performer-for-thurs-par-pharmaceutical-companies/17743</link>
		<comments>http://www.stockbloghub.com/2009/10/15/prx-top-performer-for-thurs-par-pharmaceutical-companies/17743#comments</comments>
		<pubDate>Thu, 15 Oct 2009 22:29:17 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[Hi Tech Pharmacal Company Inc]]></category>
		<category><![CDATA[HITK]]></category>
		<category><![CDATA[Impax Laboratories Inc]]></category>
		<category><![CDATA[IPXL]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[RDY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=17743</guid>
		<description><![CDATA[Par Pharmaceutical Companies, Inc. (PRX) received a brokerage firm upgrade today, which is helping it to gain during a rather muted morning session. In addition, PRX has been enjoying rising earnings estimates that have pushed the 2009 and 2010 Zacks Consensus Estimates higher in just the past 7 days. The company made the Zacks #1 Rank Top Performers List for Thursday with shares that are up approximately 4.4%. Volume is at 716,000 shares; above the daily average of 301,000. Par Pharmaceutical develops, manufactures and markets generic drugs and innovative branded pharmaceuticals for specialty markets. It is part of the Medical-Generic Drugs industry. There are 3 other names from this space on today&#8217;s Zacks #1 Rank List: Dr. Reddy&#8217;s Laboratories Ltd. (RDY), Hi-Tech Pharmacal Company, Inc. (HITK) and Impax Laboratories, Inc. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/15/prx-top-performer-for-thurs-par-pharmaceutical-companies/17743/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

